Pharmacokinetic and tolerability study of a novel 17β-estradiol and progesterone intravaginal ring in sheep

D. R. Friend\textsuperscript{1}, H. Weiss, B. A. Martell\textsuperscript{2}, E. R. Richardson\textsuperscript{3}, G. D. Constantine\textsuperscript{4}, L. A. Iciek\textsuperscript{5}, S. M. Davis\textsuperscript{6}, J. D. Vidal\textsuperscript{6}, P. R. Mayer

\textsuperscript{1}Daré Bioscience, \textsuperscript{2}Yale University School of Medicine, \textsuperscript{3}Richardson Consulting, \textsuperscript{4}EndoRheum Associates, \textsuperscript{5}Biologics Consulting Group, \textsuperscript{6}MPI Research, A Charles River Company

CONCLUSIONS

This study demonstrated the safety and tolerability of a novel EVA E2/P combination IVR in a relevant animal species. The DARE-HRT1 IVRs were well tolerated with demonstrable release profiles of both E2 and P that are projected to be efficacious and with comparable bioavailability to currently marketed products. These results support the progression of this combination product into human clinical studies.

REFERENCES


FUNDING

Funding of this work was provided by Juniper Pharmaceutica. The technology has subsequently been acquired by Daré Bioscience, San Diego, CA